Literature DB >> 11414656

Role of cyclic nucleotide phosphodiesterase isoenzymes in contractile responses of denuded rat aorta related to various Ca2+ sources.

M A Noguera1, M D Ivorra, C Lugnier, P D'Ocon.   

Abstract

We have examined the cyclic nucleotide phosphodiesterase isoforms (PDE) involved in the contractile response of rat aorta to different agonists and different experimental procedures for use in functional studies. The inhibitory effect of AAL 05 on the different PDEs isolated from bovine aortic smooth muscle was examined. Compound AAL 05 appeared to be a selective PDE3 inhibitor. We analyzed the ability of the non-selective inhibitor IBMX (3-isobutyl-1-methylxanthine) and the isoenzyme selective inhibitors nimodipine (type 1), AAL 05 (6-(N-methyl-N-cyclohexyl butyl carboxamide) quinolin-2-one) and SK&F 94120 (5-(4-acetamidophenyl) pyrazin-2(1H)-one; type3), rolipram (type4) and zaprinast (type5) to affect the contractile responses of denuded rat aortic rings to KCl (80 mM) and noradrenaline (NA, 1 microM) in the presence or absence of extracellular Ca2+. Rolipram (10-100 microM) and zaprinast (1-100 microM) failed to relax the aortic strips, but IBMX (0.1-30 microM), nimodipine (1 fM10 microM), AAL 05 (0.01-100 microM) and SK&F 94120 (0.1-100 microM) produced a concentration-dependent relaxation or inhibition of contractile responses to the different agonists, but the pIC50 obtained for each inhibitor was different depending on the experimental procedure. Except for nimodipine (a Ca2+ channel blocker), all the PDE inhibitors showed the following rank of potency: pIC50 on NA-induced contractions in Ca2+-free medium > pIC50 on NA-induced contractions in Ca2+-containing solution > pIC50 on depolarizing solution-induced contraction. This ranking apparently depends on the differences in the Ca2+ sources. We obtained a good correlation between the pKi of PDE3 inhibitors in biochemical studies and the pIC50 on NA-induced contraction in Ca2+-free medium. In conclusion, PDE1 and PDE3 isoenzymes play an important role as modulators of rat aortic smooth muscle contractility regardless of the experimental procedure used. Since intracellular mechanisms are more dependent on PDE activity, experimental procedures performed in absence of extracellular calcium are the most suitable for analyzing the modulatory role of PDE inhibitors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11414656     DOI: 10.1007/s002100100397

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  5 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Study of the mechanisms involved in the vasorelaxation induced by (-)-epigallocatechin-3-gallate in rat aorta.

Authors:  Ezequiel Alvarez; Manuel Campos-Toimil; Hélène Justiniano-Basaran; Claire Lugnier; Francisco Orallo
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

3.  Comparative study of the vasorelaxant activity, superoxide-scavenging ability and cyclic nucleotide phosphodiesterase-inhibitory effects of hesperetin and hesperidin.

Authors:  Francisco Orallo; Ezequiel Alvarez; Hélène Basaran; Claire Lugnier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-11-17       Impact factor: 3.000

4.  PDE1A inhibition elicits cGMP-dependent relaxation of rat mesenteric arteries.

Authors:  Makhala Michell Khammy; Thomas Dalsgaard; Peter Hjørringgaard Larsen; Claus Tornby Christoffersen; Dorte Clausen; Lars Kyhn Rasmussen; Lasse Folkersen; Morten Grunnet; Jan Kehler; Christian Aalkjaer; Jacob Nielsen
Journal:  Br J Pharmacol       Date:  2017-10-15       Impact factor: 8.739

5.  Inhibitory effects and underlying mechanism of 7-hydroxyflavone phosphate ester in HeLa cells.

Authors:  Ting Zhang; Jiang Du; Liguo Liu; Xiaolan Chen; Fang Yang; Qi Jin
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.